Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 388 record(s)

Req # A-2020-001559

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-114753-121.

Organization: Health Canada

6 page(s)
December 2023

Req # A-2021-001257

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-110193-864.

Organization: Health Canada

28 page(s)
December 2023

Req # A-2021-001352

Adverse Drug Reactions (ADRs) for METFORMIN HYDROCHLORIDE. Report numbers: 000941450, 000945394, E2B_03648580, E2B_03588394, E2B_03983031, 000941402, E2B_03925680, 000945402, E2B_04013536, E2B_03705957, 000942086, 000945606, E2B_03686270, E2B_03524755, 000953437, 000933180, E2B_03963675, E2B_03631002.

Organization: Health Canada

266 page(s)
December 2023

Req # A-2021-001369

Adverse Drug Reactions (ADRs) for Januvia. Report numbers: E2B_02010119, E2B_02010120, E2B_02020982, 000719928, 000720126, 000720300, 000721169, E2B_00412992, 000625403, 000720290.

Organization: Health Canada

406 page(s)
December 2023

Req # A-2021-001585

Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_03790676, E2B_04462995, E2B_03578873, E2B_03566753, E2B_03595424, E2B_03578877, E2B_03542706, E2B_03633218, E2B_03705234, E2B_03839314, E2B_03626734.

Organization: Health Canada

227 page(s)
December 2023

Req # A-2022-001119

Adverse Drug Reactions (ADRs). Report numbers: E2B_05667245, E2B_05643061, E2B_05643946, E2B_05657020, E2B_05657026, 1012093, 1005259, E2B_05642958, E2B_05643023.

Organization: Health Canada

5215 page(s)
December 2023

Req # A-2022-001176

Adverse Drug Reactions (ADRs). Report numbers: E2B_04972078, E2B_05082647, E2B_05116898, E2B_05133704, E2B_05314817, E2B_05331286.

Organization: Health Canada

116 page(s)
December 2023

Req # A-2022-001192

Adverse Drug Reactions (ADRs). Report numbers: 001014921, E2B_05801904, E2B_05802015, E2B_05802374, E2B_05803168, E2B_05803333, E2B_05846923.

Organization: Health Canada

96 page(s)
December 2023

Req # A-2022-001253

Adverse Drug Reactions (ADRs) for PANTOPRAZOLE SODIUM. Report numbers: E2B_05804048, E2B_05806287, E2B_05824479, E2B_05825410, E2B_05825749, E2B_05826892, E2B_05828141, E2B_05851183, E2B_05865879. ADR for PANTOPRAZOLE MAGNESIUM. Report number: 001012808.

Organization: Health Canada

465 page(s)
December 2023

Req # A-2022-001356

Adverse Drug Reactions (ADRs) for MESALAZINE. Report numbers: E2B_05926116, E2B_05879303, E2B_05951268, 001018724, 001018203, 001018211, 001017894. ADRs for MESALAMINE. Report numbers: E2B_05929118, E2B_05960176. ADR for TEDUGLUTIDE. Report number: E2B_05932422.

Organization: Health Canada

309 page(s)
December 2023

What's new in open government?

Date modified: